Orpro Therapeutics Inc.

Orpro Therapeutics Inc., a for-profit biopharmaceutical company headquartered in San Diego, California, operates as a prime recipient of federal research grants focused on engineered biologic therapeutics for inflammatory and oxidative-stress conditions. The vendor's recent federal footprint consists entirely of grant awards from the National Institutes of Health (NIH) and the Defense Health Agency, with 83% prime-recipient activity and one sub-recipient role.

Orpro's grant portfolio centers on the development and preclinical validation of ORP100S, an engineered monothiol variant of human thioredoxin-1 designed to address oxidative, inflammatory, and muco-obstructive stresses. In September 2025, the National Institute of Allergy and Infectious Diseases (NIAID) awarded Orpro $508,988 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate ORP100S as a treatment for radiation-induced lung injury through in vivo studies in a mouse tumor-implantation model, with performance in San Diego and completion by August 31, 2027. The Defense Health Agency previously funded Orpro under a project grant running from July 1, 2022, through June 30, 2025 (extended twelve months via modification), to develop ORP100S as an inhaled treatment for acute viral lung injury. Orpro also appears as a sub-recipient under a University of Oklahoma prime grant from February 2026 focused on thioredoxin derivatives for radiation mitigation. Additional NIH work includes grants from the National Heart Lung and Blood Institute and the Office of the Director.

Orpro's visible federal grant footprint spans six awards totaling $7 million obligated across five customer agencies within HHS and DoD. Activity is sparse and episodic — one award in 2012, two in 2018, then gaps until 2022, 2025, and 2026 — reflecting the developmental and early-stage nature of its biologic candidate portfolio. One award reaches completion within the next twenty-four months and faces potential recompete or follow-on opportunity.